-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellebrite (CLBT) Stock May Be 27% Undervalued Despite U.S. Redomiciliation Plans

Simply Wall St·11/15/2026 02:30:09
Listen to the news

Cellebrite DI has delivered a 44.1% gain over the past three years, yet the share price is currently well below where it started the year. That puts the focus squarely on what the business is generating in cash terms. With fresh headlines around growth plans, new leadership and a legal review, the question for you is whether the current valuation can be explained by the cash flows the company is expected to produce.

  • The 44.1% rise over three years means long term holders have real gains at stake, so any mismatch between price and underlying cash generation matters more now.
  • Recent growth in recurring revenue, investment in the Genesis AI platform and the plan to redomicile to the U.S. can reshape expectations for future cash inflows and the timing of those streams.
  • Prefer to judge Cellebrite DI on earnings? See why Cellebrite DI's 44.7x P/E tells a different valuation story.

For investors, the debate is whether Cellebrite DI's current share price is adequately explained by its cash flows when measured against a Discounted Cash Flow (DCF) view of intrinsic value.

If you want a broader reference point on how other companies tied to AI and digital infrastructure are being priced, it is worth scanning 53 AI infrastructure stocks.

Does Cellebrite DI Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Cellebrite DI by projecting future free cash flows and discounting them back to today in dollars. On this view, the latest twelve month Free Cash Flow sits at about $156.0 million, with the model assuming growing cash generation over time rather than a one off spike.

Across the next decade, the projections point to Free Cash Flow rising into the low to mid $200 million range and then continuing to build from there. This helps explain why the DCF outcome sits meaningfully above the current share price of $11.53. The recent investigation following Cellebrite DI's revenue guidance cut gives a clear reason why some investors are cautious even though the cash flow profile used in the model still supports a higher intrinsic value than the market price. Find out what Cellebrite DI could be worth using our Discounted Cash Flow (DCF) estimate.

The Cellebrite DI Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cellebrite DI pick up where the valuation puzzle leaves off. They spell out which specific paths for Cellebrite DI's growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's market price. Each narrative ties a fair value range to a particular set of potential catalysts and risks, so you can track over time which version of the story appears to be unfolding on the Community page.

One of the top narratives on Cellebrite DI: 25% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"The main thing that has to go right is that Cellebrite DI converts its AI and cloud products, including Genesis, Guardian and new defense and intelligence offerings, into sustained ARR growth while managing procurement friction..."

Discover why this Narrative puts Cellebrite DI at 25% undervalued.

Cellebrite DI’s price is only one part of the real investment question

Cash flow models tell only part of the Cellebrite DI story, since recent research checks have flagged specific risks that deserve a closer look before you commit fresh capital. Take a closer look at 1 warning sign before settling on a valuation.